相关临床试验
15
7 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2014
进行中（未招募）
3
20.0%
已完成
2
13.3%
尚未招募
4
26.7%
招募中
4
26.7%
终止
1
6.7%
Unknown
1
6.7%
暂无批准数据
- Australian researchers identified low miR-342 levels and high E2F pathway activity as drivers of metastasis in triple-negative breast cancer (TNBC), published in EMBO Molecular Medicine. - In pre-clinical models, restoring miR-342 markedly reduced cancer spread to organs including the lungs and bones. - The existing CDK4/6 inhibitor palbociclib significantly reduced metastatic tumor growth in models with low miR-342, suggesting a repurposing opportunity. - Measuring miR-342 could identify a TNBC subgroup most likely to benefit from CDK4/6 inhibitors, with patient-derived models planned before clinical trials.
- Ribociclib (Kisqali) is now subsidized on Australia's Pharmaceutical Benefits Scheme for early-stage breast cancer patients with hormone receptor-positive, HER2-negative disease at high risk of recurrence. - The NATALEE trial demonstrated that adding ribociclib to standard hormone therapy reduced cancer recurrence risk by 28.5% compared to hormone therapy alone in 5,101 patients. - The PBS listing saves patients over $140,000 in treatment costs, as the drug previously cost approximately $3,700-$4,000 per month for three years without subsidy. - This development provides treatment options for approximately 70% of early-stage breast cancer cases, representing the most common subtype of the disease.
